Theratechnologies Shares Financial Results for Q2 2017

Theratechnologies (TSX:TH) released their financial reports for the second quarter of 2017.
As quoted in the press release:

“Our second quarter results are characterized by continued EGRIFTA^® revenue growth and significant planned investments required to prepare for the launch of ibalizumab. As a matter of fact, EGRIFTA^® sales are the best we ever recorded for a second quarter. This was achieved without having started to reap the benefits from the expanded sales contingent which is now fully operational and will extend our reach to almost 5,000 U.S. physicians instead of 1,100. Already, we are seeing the positive impact of the expanded sales team,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
“We also achieved several milestones towards the launch of ibalizumab in the second quarter. The Biologics Licence Application was completed, we reached an agreement with our partner, TaiMed Biologics Inc., for the commercial rights to ibalizumab in Europe and we just received confirmation from the FDA that ibalizumab will be evaluated under the priority review process with a target action date of January 3^rd, 2018. Ever since we acquired the rights to ibalizumab in the United States, our goal has been to have the right team in place to ensure an optimal launch if a positive decision is received from the FDA. I am quite satisfied with our level of preparedness at this stage,” concluded Mr. Tanguay.

Click here to read the full press release.

Source: www.marketwired.com